New Brunswick, NJ – Johnson & Johnson announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global dementia discovery fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer's disease. The investment will be made through its affiliate venture arm, Johnson & Johnson Innovation.
2 Comments
Port Murray, NJ – Biocia Inc., a New Jersey-based biotechnology company announced the recent commercialization of their viscoadaptive eye drop innovations in a preservative-free delivery system through key Biocia licensing partners in North America for Ocular Surface Disorder (OSD) such as dry eye disease (DED). Biocia licensing partners include Oasis Medical Inc. in the United States (Oasis Tears® PF) and I-MED Pharma in Canada (i-drop® Pur and i-drop® Pur GEL).
Princeton, NJ - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo(nivolumab) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo is the first and only PD-1 (programmed death receptor-1) therapy to demonstrate overall survival in previously treated metastatic squamous NSCLC. Opdivo demonstrated significantly superior overall survival (OS) vs. docetaxel, with a 41% reduction in the risk of death (hazard ratio: 0.59 [95% CI: 0.44, 0.79; p=0.00025]), in a prespecified interim analysis of a Phase III clinical trial. The median OS was 9.2 months in the Opdivo arm (95% CI: 7.3, 13.3) and 6 months in the docetaxel arm (95% CI: 5.1, 7.3).
River Edge, NJ - Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that the Renal Research Institute (“RRI”) is conducting an evaluation of the company’s hemodiafiltration (“HDF”) system. The Nephros HDF system is comprised of Nephros’ patented OLpur MD220 Mid-Dilution Hemodiafilter and OLpur H2H Hemodiafiltration Module. The module is designed for use with a standard hemodialysis machine to enable hemodiafiltration treatment of patients with chronic renal failure.
Summit, NJ - These are exciting times for Celgene and promising times for the patients we serve. We continue to deliver on multiple opportunities, translating the potential of transformational science into disease-altering and life-enhancing innovative medicines with the goal of helping patients with critical unmet medical needs worldwide live longer and better lives. This dedication to patients is aligned with our corporate vision, mission and values and reflects our unwavering commitment to put patients first. By advancing the course of healthcare through bold scientific pursuits and medical innovation we are making it possible for societies to progress and economies to prosper.
New Brunswick, NJ – Rutgers, The State University of New Jersey, developed a new Business Portal, designed in consultation with industry leaders to serve New Jersey’s corporate community. The Business Portal offers users easy access to four key areas—research, technology licensing, professional development and recruiting—and provides two robust internal search functions and clear pathways to Rutgers’ Corporate Engagement Team, Office of Research Commercialization and Rutgers Translational Sciences.
Washington D.C. - Executive vice Executive vice president of corporate affairs of Pfizer, Sally Susman explains the high cost of drug creation in Quartz.
|
Do not miss a single innovative moment and sign up for our newsletter!
|